BioLife Solutions (NASDAQ:BLFS) Insider Karen Foster Sells 415 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen Foster sold 415 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $26.74, for a total transaction of $11,097.10. Following the completion of the transaction, the insider owned 192,838 shares in the company, valued at approximately $5,156,488.12. This trade represents a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

BioLife Solutions Price Performance

NASDAQ BLFS traded down $0.14 during trading hours on Friday, reaching $26.54. 268,903 shares of the stock traded hands, compared to its average volume of 454,795. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -221.15 and a beta of 1.97. The stock has a 50 day simple moving average of $26.44 and a two-hundred day simple moving average of $24.24. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.62.

Hedge Funds Weigh In On BioLife Solutions

Several large investors have recently made changes to their positions in the business. Amalgamated Bank boosted its position in shares of BioLife Solutions by 3.5% in the 3rd quarter. Amalgamated Bank now owns 10,898 shares of the medical equipment provider’s stock worth $278,000 after purchasing an additional 366 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in BioLife Solutions by 12.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 441 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in BioLife Solutions by 2.9% during the third quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider’s stock valued at $454,000 after buying an additional 500 shares during the last quarter. Isthmus Partners LLC boosted its holdings in BioLife Solutions by 0.4% in the second quarter. Isthmus Partners LLC now owns 132,125 shares of the medical equipment provider’s stock worth $2,846,000 after acquiring an additional 509 shares in the last quarter. Finally, Sei Investments Co. grew its stake in shares of BioLife Solutions by 0.5% in the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock worth $2,695,000 after acquiring an additional 547 shares during the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of BioLife Solutions in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Zacks Research raised BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Finally, Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.20.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.